drugset

drugset / Trial / NCT06817720

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

NCT06817720 ↗

Phase 2 Recruiting 50 enrolled M.D. Anderson Cancer Center Ascentage Pharma Group Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.

Timeline

Start: 2025-10-13
Primary completion: 2027-03-07
Completion: 2027-03-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olverembatinib	Small molecule	30 mg	Oral

Indications